https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after
0
0
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly
12/18/25 at 11:46am
Organization
Lilly.com
48 words
0
Comments
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
You are the first to view
Create an account or login to join the discussion